Cytokinetics EVP exercises options, sells 886 shares

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and related share sale.

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and related share sale. On March 2, 2026, he exercised an Incentive Stock Option for 886 shares, converting it into 886 shares of common stock at $37.63 per share. The same day, he then sold 886 shares of common stock at $61.62 per share in an open-market transaction. After these transactions, he held 50,440 shares of Cytokinetics common stock directly. The option grant referenced in the filing vests in equal monthly installments over four years from its grant date.

Insider Trade Summary

Exercise and Sale: 886 shares ($21K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 886 shs ($55K)

Approx. gross sale proceeds $55K

Approx. exercise cost $33K

Approx. pre-tax spread $21K

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (Right to Buy)	886	$0.00	$0.00
Exercise	Common Stock	886	$37.63	$33K
Sale	Common Stock	886	$61.62	$55K

Holdings After Transaction: Incentive Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 50,440 shares (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Cytokinetics (CYTK) EVP Andrew Callos report?

Andrew Callos reported exercising an incentive stock option for 886 shares and selling 886 Cytokinetics common shares. The exercise converted options into stock, and the same number of shares was then sold in an open-market transaction on March 2, 2026.

How many Cytokinetics (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 886 shares of Cytokinetics common stock at $61.62 per share. This open-market sale occurred on March 2, 2026, immediately after acquiring the same number of shares through an option exercise.

What was the option exercise reported by Cytokinetics (CYTK) EVP Andrew Callos?

He exercised an Incentive Stock Option for 886 shares, converting it into 886 Cytokinetics common shares at an exercise price of $37.63 per share. The option grant vests monthly over four years from the original grant date.

How many Cytokinetics (CYTK) shares does Andrew Callos own after these transactions?

Following the reported option exercise and share sale, Andrew Callos directly owns 50,440 shares of Cytokinetics common stock. This figure reflects his direct holdings after both the acquisition and disposition on March 2, 2026.

What does transaction code M and S mean in the Cytokinetics (CYTK) Form 4?

Code M indicates the exercise or conversion of a derivative security, here an Incentive Stock Option into common stock. Code S indicates a sale of common stock in the open market or a private transaction, as used for the 886-share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		M		886	A	$37.63	51,326	D
Common Stock	03/02/2026		S		886	D	$61.62	50,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$37.63	03/02/2026		M			886	04/01/2025(1)	03/01/2032	Common Stock	886	$0	0	D

Explanation of Responses:

1. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.